Lanosterol 14-alpha demethylase (EC 22.214.171.124; UniProt Q16850; also known as CYP51A1, CYPL1, CYPLI, Cytochrome P450 51A1, Cytochrome P450, family 51, subfamily A, polypeptide 1, Cytochrome P450-14DM, Cytochrome P45014DM, Cytochrome P450L1, Cytochrome P450LI, LDM, Sterol 14-alpha demethylase) is encoded by the CYP51A1 (also known as CYP51) gene (Gene ID 1595) in human. Cytochromes P450 (CYP) proteins are primarily membrane-associated oxidases located either in the inner membrane of mitochondria or in the endoplasmic reticulum where they function as the terminal enzymes in electron transfer chains. In addition to processing endogenous substrates, CYPs also function to metabolize exogenous drugs and potentially toxic chemicals. The human CYP superfamily consisits of 57 genes and more than 59 pseudogenes divided into 18 families and 43 subfamilies. CYP51A1 represents the only member of the CYP51 subfamily and is involved in the conversion of lanosterol to 4,4-dimethylcholesta-8(9),14,24-trien-3 -ol. Products generated by the CYP51 reaction are vital intermediates in pathways leading to the formation of cholesterol in humans, ergosterol in fungi, and other types of sterols in plants. Sterols play an important structural role in the regulation of membrane fluidity and permeability, which influence the functions of enzymes, ion channels, and other cell components embedded within.
Clone N6-P2H5*G8 was raised against a CYP51A1 C-terminal sequence 100% conserved among human, mouse, and rat species. Target band was detected only in lysate from CYP51A1-transfected, but not from untransfected, cells (Swan, R., et al. (2016). Oncotarget. In press).
Ovalbumin-conjugated linear peptide corresponging to a sequence near the C-terminus of human/mouse/rat CYP51A1.
Anti-CYP51A1 Antibody, clone N6-P2H5*G8, Cat. No. MABS1259, is a highly specific mouse monoclonal antibody that targets CYP51A1, validated for use in Immunohistochemistry (Paraffin) and Western Blotting.
Immunohistochemistry Analysis: Clone N6-P2H5*G8 hybridoma culture supernatant detected an upregulated CYP51A1 immunoreactivity in human colon carcinoma tissue relative to that in normal liver tissue.
Immunohistochemistry Analysis: A representative lot detected increased CYP51A1 expression in formalin-fixed, paraffin-embedded primary colorectal cancer tissue than in normal colonic mucosa. Significantly reduced CYP51A1 expression was found in lymph node metastasis compared to Dukes C (stage 3) colorectal cancer (Swan, R., et al. (2016). Oncotarget. In press).
Western Blotting Analysis: A representative lot detected a target band in lysate from CYP51A1-transfected, but not from untransfected, cells (Swan, R., et al. (2016). Oncotarget. In press).
Evaluated by Western Blotting in human liver microsome lysate.
Western Blotting Analysis: A 1:125 dilution of this antibody detected CYP51A1 in 50 µg of human liver microsome lysate.
~50 kDa observed. 56.81/46.31 kDa (human isoform 1/2), 56.78 kDa (mouse), and 56.71 kDa (rat) calculated. Uncharacterized bands may be observed in some lysate(s).
Protein G purified.
Purified mouse IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4) 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Concentration: Please refer to lot specific datasheet.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.